- Frencken’s 1H23 earnings of S$12m (-54% y-o-y) is in line with expectation, accounting for 46% of our full-year estimate. 1H23 revenue fell 9% y-o-y as all segments saw revenue declines, with the exception of medical (+29% y-o-y) and analytical & life sciences (+7% y-o-y).
- - Read this at SGinvestors.io -
- We raise our target price for Frencken by 28% to S$1.00 after rolling over our valuation base year. Upgrade Frencken to BUY.
1H23 earnings of S$12m (-54% y-o-y) was in line with expectation.
- - Read this at SGinvestors.io -
Revenue declined across four segments, while that for medical and analytical & life sciences rose.
- Read more at SGinvestors.io.
